Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity

Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations

(2015) Navneet Sangha et al.   NEOPLASIA

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung

(2011) Zvi Granot et al.   CANCER CELL

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma

(2011) Valerie Chew et al.   GUT

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Inherited Determinants of Ovarian Cancer Survival

(2010) E. L. Goode et al.   CLINICAL CANCER RESEARCH

The Fallopian Tube

(2010) Shannon Salvador et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

The chemiluminescence based Ziplex® automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip® expression profiles

(2009) Michael CJ Quinn et al.   Journal of Translational Medicine

Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer

(2009) Michael C.J. Quinn et al.   MOLECULAR CARCINOGENESIS

Characterization of three new serous epithelial ovarian cancer cell lines

(2008) Véronique Ouellet et al.   BMC CANCER

Introduction: the immune response against dying cells

(2008) Laurence Zitvogel et al.   CURRENT OPINION IN IMMUNOLOGY

DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma

(2008) Qinghua Feng et al.   GYNECOLOGIC ONCOLOGY

Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes

(2007) P.M. WOJNAROWICZ et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

(2007) R. SALANI et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER